title: Probucol delays progression of diabetic nephropathy.
abstract: Probucol has antioxidant and cholesterol-lowering effects. This study examined the effect of probucol on progression of diabetic nephropathy. We performed a randomized, open trial on 102 type 2 diabetes patients with clinical albuminuria (urinary albumin excretion >300 mg/g Cr). Fifty-one patients were assigned to probucol treatment (500 mg/day) and 51 to no probucol treatment. Among all patients, 40 who had serum creatinine >or=2mg/dl at baseline were defined as advanced cases. All patients were followed for a maximum 3 years. HbA1c levels were not different between two groups. High-density lipoprotein cholesterol decreased significantly in probucol group. Increase in urinary protein (g/day/month) was significantly greater in non-probucol than in probucol group. Hemodialysis was initiated in 23 patients (10 in probucol group and 13 in non-probucol group). The mean interval to initiation of hemodialysis was significantly longer in probucol group (20.7+/-8.2 months) than in non-probucol group (11.3+/-7.4 months). In advanced cases, increases of both serum creatinine and urinary protein were significantly suppressed in probucol group. In advanced cases, the hemodialysis-free rate was significantly higher in probucol group than in non-probucol group. These results suggest that probucol may suppress the progression of diabetic nephropathy.
authors: The Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
authors: Kei
authors: K
authors: Endo
authors: Yoh
authors: Y
authors: Miyashita
authors: Hidehisa
authors: H
authors: Sasaki
authors: Masahiro
authors: M
authors: Ohira
authors: Atsuhito
authors: A
authors: Saiki
authors: Nobukiyo
authors: N
authors: Koide
authors: Masaki
authors: M
authors: Otsuka
authors: Tomokazu
authors: T
authors: Oyama
authors: Murano
authors: M
authors: Takeyoshi
authors: Yoshiaki
authors: Y
authors: Ito
authors: Koji
authors: K
authors: Shirai
mesh_terms: D000368:Aged; D000419:Albuminuria; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D018450:Disease Progression; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000706:statistics & numerical data
chemical_list: D000924:Anticholesteremic Agents; D002784:Cholesterol; D008076:Cholesterol, HDL; D003404:Creatinine; D006442:Glycated Hemoglobin; D008055:Lipids; D011341:Probucol